CClinicalTrials.gg
RecruitingNCT05164263EASEUpdated Jan 22, 2026

Real World Safety & Efficacy Experience of Empagliflozin With or Without Metformin in T2DM Patients - EASE Study

A Phase 4 interventional study of Empagliflozin in Type II Diabetes Mellitus, Efficacy, Self and Safety Issues, sponsored by Getz Pharma. Recruiting at 6 sites in 5 countries. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-22.

Sponsored by Getz Pharma · Phase 4, Interventional, and Treatment

Phase
Phase 4
Study type
Interventional
Enrollment
2,000
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Study Objective To evaluate the safety and tolerability of Empagliflozin with or without metformin in patients with Type II Diabetes Mellitus in the Pakistani population.

Study design Open-label, prospective, observational, single arm, multi-center, post-marketing surveillance study.

Sample size The estimated sample size will be n=156. Duration of study 12 months (data lock point will be completion of 6 months' follow-up from the time of last patient's enrollment date) Safety Assessment: Patient will be monitored for Hypoglycemia, Dehydration, Hypotension, Urinary Tract Infections, Fungal Infections, Nausea, Vomiting, Diarrhea, Abdominal Discomfort, Flatulence, Asthenia, Indigestion and Other side effects (if any).

Follow up visits: After recruitment, patient is supposed to have three visits for follow-ups.

Visit 1: 4 to 6 weeks of initiation of therapy. Visit 02: At 12 weeks of initiation of therapy. Visit 03: At 24 weeks of initiation of therapy.

LABORATORY TESTING:

Reputable Lab is considered for laboratory testing of diabetes patients i.e. HbA1C%, FBG, RFT and urine R/E. The certified clinical lab will be responsible for receiving and analyzing clinical sample. Patients will have special discount of upto 50% for study related laboratory investigations.

Where in Urine Routine Examination (Urine R/E), we consider as follows:

  • Visual Examination:

    • Urine color: Normal (Yellow), Pale Yellow, Dark Yellow, Brown, Red or Pink or any other.
    • Urine clarity: Clear, slightly Cloudy, cloudy or turbidity
  • Chemical Examination:

    • Specific gravity
    • pH
    • Bilirubin
    • Urobilinogen
    • Protein
    • Ketone
    • Leukocyte Esterase
  • Microscopic Examination:

    • Red Blood Cells:
    • Epithelial Cells:
    • Amorphous:
    • Pus Cells
    • Bacteria
    • Yeast
    • Casts
    • Crystals

Where in Renal Function Test (RFT), we consider as follows:

  • Blood Urea Nitrogen (BUN): mg/dL
  • Serum Creatinine: mg/dL
  • Estimated Glomerular Filtration Rate (eGFR): mL/min/1.73 m2
02

Conditions studied

  • Type II Diabetes Mellitus
  • Efficacy, Self
  • Safety Issues
03

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

Patient with T2DM between 18 to 65 years with HbA1C 7% - 10%, who can give informed consent. Patient uncontrolled on oral antidiabetics and lifestyle modification for at least 3 months. Patient who are empagliflozin naive. eGFR ˃60 mL/min/1.73m2.

Exclusion criteria

Exclusion Criteria:

Type 1 diabetes, History of recurrent urinary tract infection (UTI), fungal infection, renal and/or hepatic dysfunctions, where RFT and Urine R/E is abnormal, Diabetic Ketoacidosis and/or hyperosmolar hyperglycemic state, severe hypoglycemia, Pregnant or lactating women, Pancreatitis, any serious complications or hypersensitivity.

04

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
2,000 participants (estimated)

Study arms

  • Experimental
    Empagliflozin naive uncontrolled T2DM on oral anti-diabetics & lifestyle modifications for 3 months

    Type 2 diabetic males \& females between 18-65 years. * HbA1c: 7.0% - 10% * eGFR ˃60 mL/min/1.73m2. * Patient who will give informed consent

    Drug: Empagliflozin

Interventions

  • DrugEmpagliflozin

    Empagliflozin + Metformin (Diampa™-M): 5mg+500mg, 5mg+850mg, 5mg+1000mg, 12.5mg+1000mg, 12.5mg+500mg, 12.5mg+ 850mg Empagliflozin Alone (Diampa™): 10mg, 25mg

05

What researchers measure

Primary outcomes

  1. SAFETY and TOLERABILITY Outcomes

    Frequency of adverse events, serious adverse events during the course of study follow-up. Percentage of patients who tolerate empagliflozin.

    Time frame: 6 months

Secondary outcomes

  1. Efficacy outcomes

    Change from baseline in HbA1c% and fasting plasma glucose to the last-observation on treatment. Change from baseline in bodyweight \& other study parameters.

    Time frame: 6 months

06

Study locations

2 of 6 sites recruiting
  • Kabul University of Medical Sciences(KUMS)
    Kabul, Afghanistan, Afghanistan
    Completed
  • Agha Khan univeristy hospital
    Nairobi, Kenya, Kenya
    • Dr. Saira Banu Sokwalla · Contact
    Recruiting
  • Lagos University Teaching Hospital
    Lagos, Nigeria, Nigeria
    • Dr. Olufemi Adetola Fasanmade · Contact
    • Dr. Andrew Enemako Uloko · Sub investigator
    • Dr. Chioma Nnachukwu · Sub investigator
    Recruiting
  • Umar Diabetes Foundation
    Islamabad, Pakistan
    Completed
  • National hospital Sri Lanka
    Colombo, Colombo, Sri Lanka
    Completed
  • NHK
    Kandy, Kandy, Sri Lanka
    Completed
07

References and documents

Publications

  • Ferrannini E, Mark M, Mayoux E. CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis. Diabetes Care. 2016 Jul;39(7):1108-14. doi: 10.2337/dc16-0330. PubMed 27289126 ↗
  • Barnett AH, Mithal A, Manassie J, Jones R, Rattunde H, Woerle HJ, Broedl UC; EMPA-REG RENAL trial investigators. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2014 May;2(5):369-84. doi: 10.1016/S2213-8587(13)70208-0. Epub 2014 Jan 24. PubMed 24795251 ↗

Individual participant data

Plan to share: No — Upon request

08

Registry details

Key details

Study ID
NCT05164263
Lead sponsor
Getz Pharma
Responsible party
Sponsor
First posted
Dec 20, 2021
Start date
Apr 1, 2021
Primary completion
Dec 31, 2026 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
Jan 22, 2026

Study contacts

Dr. Muhammad Nabeed Tahir
Contact
nabeedt@gmail.com
+923015376299
Dr. Umar Wahab
Contact
dromarwahab@yahoo.com
+923339158285
Umar Wahab
principal investigator · Umar Diabetes Foundation

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion